Renal Week 2010 Meeting Coverage


Follow our archived coverage from Renal Week - the American Society of Nephrology's annual meeting and scientific exposition - in Denver. Our coverage includes four sections below.



Everolimus May Reduce CMV Risk

DENVER—Use of everolimus (EVR) rather than mycophenolic acid (MPA) in renal transplant recipients may significant decrease the risk for cytomegalovirus events, according to a study.

Artery Size and Diabetes Predict AVF Patency

DENVER—Artery size is the only predictor of both primary and secondary patency in arteriovenous fistula (AVF) placement in hemodialysis (HD) patients, researchers reported at Renal Week 2010. The presence of diabetes predicted primary patency only.

CAB Surgery May Be Superior to Stents Long Term

DENVER—Drug-eluting stents (DES) provide the best short-term survival for dialysis patients who require coronary revascularization, but coronary artery bypass (CAB) surgery may offer better long-term survival, researchers reported at the 2010 Renal Week conference.

Novel Binder Lowers Phosphorus, LDL Cholesterol

An investigational calcium-free phosphate binder called colestilan is safe and effective for controlling phosphorus in dialysis patients, and it has no impact on calcium levels, researchers reported.

Lipid Lowering Reduces Cardiovascular Risk in CKD Patients

Cholesterol-lowering treatment with a combination of ezetimibe and simvastatin significantly decreases the likelihood of major atherosclerotic events in patients with chronic kidney disease (CKD), according to the findings of the five-year Study of Heart and Renal Protection (SHARP) trial.

Investigational Drug May Reverse CKD

Investigational Drug May Reverse CKD

DENVER—Recent trial data suggest that an investigational agent called bardoxolone methyl may improve renal function in type 2 diabetics with moderate to severe chronic kidney disease (CKD).

Lowering Cholesterol Reduces CV Event Risk in CKD Patients

DENVER—Cholesterol-lowering treatment with a combination of ezetimibe and simvastatin significantly decreases the likelihood of major atherosclerotic events in patients with chronic kidney disease (CKD), according to the findings of the five-year Study of Heart and Renal Protection (SHARP) trial.

Positive Phase 2b Study Results Announced for Bardoxolone Methyl

Pablo Pergola, MD, PhD, Research Director for Renal Associates PA and Clinical Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio discusses the study on Positive Phase 2b Study Results for Bardoxolone Methyl that was shown at Renal Week 2010 in Denver.

The Treatment of Resistant Nephrotic Syndrome with Acthar Gel (ACTH)

Andrew S. Bomback, MD, MPH, Assistant Professor of Clinical Medicine, Columbia University, New York discusses his study on the treatment of resistant nephrotic syndrome with Acthar Gel (ACTH) during Renal Week 2010 in Denver.

Worsening Kidney Disease in Blacks Linked to Gene Variant

A common gene variant appears to be associated with a sharply increased risk of progressive kidney disease in African Americans (AAs) with hypertensive nephrosclerosis, according to a study presented at Renal Week 2010 in Denver.

FGF-23 Linked to Cinacalcet Use

Fibroblast growth factor 23 (FGF-23) is positively associated with cinacalcet use, calcium, and phosphorus in hemodialysis (HD) patients, according to a study presented at Renal Week 2010 in Denver.

Phosphate, FGF-23 Rise in PD Patients as Residual Renal Function Declines

Serum phosphate and fibroblast growth factor 23 (FGF-23) levels increase in incident peritoneal dialysis (PD) patients increase as residual renal function declines, according to researchers who presented their findings at Renal Week 2010 in Denver.

H1N1 Vaccine May Not Protect Most Kidney Transplant Recipients

Most renal transplant recipients may not benefit from being vaccinated against the H1N1 influenza virus, according to a new German study presented at Renal Week 2010 in Denver.

Target Higher Hb May Be Renoprotective in Tx Patients

Researchers at Renal Week 2010 in Denver have reported on what they believe is the first prospective, randomized study to show that targeting a serum hemoglobin (Hb) level of 13 g/dL or higher has a renoprotective effect in kidney transplant patients.

SHPT in Dialysis Patients Associated with Greater Mortality, Morbidity

New data presented at Renal Week 2010 in Denver confirm the high morbidity and mortality associated with secondary hyperparathyroidism (SHPT) in dialysis patients, emphasizing the need for early referral as well as other therapeutic interventions.

Sign Up for Free e-newsletters